2023 Impact Factor: 0.9
2023 CiteScore: 1.8
pISSN: 1735-7020
eISSN: 2008-238x
Editor-in-Chief:
Gholamhossein Edrissian, Pharm. D.
This journal is a member of, and subscribes to the principles of, the Committee on Publication Ethics (COPE).
Types of Manuscripts
Original articles:
These include randomized controlled trials, intervention studies, studies of screening and diagnostic test, outcome studies, and cost-effectiveness analyses. The text of original articles amounting to utmost 3000 words (excluding Abstract, References and Tables) should include Title; the Abstract; Introduction; Materials & Methods; Results; Discussion; Conclusion; Acknowledgement; References, Tables and Figures (Not more than 4500 words).
Review Articles:
They should be written by authors considered experts on the subject. Therefore, the corresponding author of the review article must be one of the authors of at least three articles presented in Reference section. Systematic reviews and meta-analysis are more welcomed and they should respectively follow the PRISMA (http://www.prisma-statement.org/) and MOOSE guidelines (http://www.consort-statement.org). Review articles must include an abstract of no more than 250 words, a main text between 2000-3000 words excluding up to 90 references, and up to 6 tables and/or figures (altogether 5500-6000 words).
Short Communications:
Short communications are brief reports of research works containing new findings, which are not exceeding 2500 words from introduction through references. The Short Communication consists of Abstract, main body including Introduction, Methods, Results, Discussion, Conclusion; Acknowledgement, References, Tables and Figures (Not more than 3000 words).
Case reports:
Case reports are accepted provided they are of exceptional interest for readers. The case report consists of Abstract (unstructured), Introduction, Case Report, Discussion, Acknowledgements, and References. Case reports must not exceed 1,000 words, 15 references and a reasonable amount of tables and/or figures (Not more than 2500 words).
Letters to the Editor:
Letters could be of two types, commenting either on recently published articles or reporting cases, outbreaks, or original research. The former must be received within 2 months of publication of the article to which they refer and should be no longer than 500 words. The latter should contain no more than 1000 words altogether including up to 10 references and 2 figures and/or tables. They should not be divided into sections.
Other:
Guest Editorial is solicited by the Editorial Board. National Reports or similar cases are accepted based on confirmation by Editorial Board.
11.The corresponding author will be supplied with 4 free issues.
The Final Checklist
The authors are requested to mark a copy of the following form and attach it to the covering letter
A covering Letter
• Three copies of complete manuscript are presented.
• The manuscript has been read and approved by all listed authors.
• Title page contains the title, name(s), degree(s) affiliation(s) and addresses, Tel, Fax, and E-mail of the author(s).
• Abstract is in structured format that mentions Introduction; Materials & Methods; Results; Conclusion and Keywords.
• Figures / illustrations are in high quality art work, along with their captions.
• Bibliographical references are mostly up-to-date and are numbered consecutively as they occur in the text and at the end of the manuscript are numbered accordingly.
• All human and animal studies are approved by respective Ethics Committee.
• Hereby we accept liability for the scientific integrity of the manuscript contents.
Correspondent author
Name:
Date:
E-mail or address:
Signature:
Co- authors
Name:
Date:
Signature:
Submission Preparation Checklist
As part of the submission process, authors are required to check off their submission's compliance with all of the following items, and submissions may be returned to authors that do not adhere to these guidelines.
Privacy Statement
The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.
2023 Impact Factor: 0.9
2023 CiteScore: 1.8
pISSN: 1735-7020
eISSN: 2008-238x
Editor-in-Chief:
Gholamhossein Edrissian, Pharm. D.
This journal is a member of, and subscribes to the principles of, the Committee on Publication Ethics (COPE).
All the work in this journal are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |